𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Estimating recurrences prevented from using trastuzumab in HER-2/neu–positive adjuvant breast cancer in the United States

✍ Scribed by Mark D. Danese; Deepa Lalla; Melissa Brammer; Quan Doan; Kevin Knopf

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
250 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of trastuzum
Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
✍ Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)‐positive breast cancer. A cost‐effectiveness analysis was performed to assess clinical and economic implications of adding t

Trastuzumab plus docetaxel in HER-2/neu-
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma : Final results from the California Cancer Consortium screening and Phase II trial
✍ Primo N. Lara Jr.; Karen Giselle Chee; Jeff Longmate; Christopher Ruel; Frederic 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

## Abstract ## BACKGROUND Overexpression of the HER‐2/__neu__ oncoprotein has been reported to occur in ≤ 60% of patients with prostate carcinoma and to correlate with shortened survival. Trastuzumab is a humanized monoclonal antibody to the HER‐2 receptor and has activity against HER‐2–positive b